![Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial - The Lancet Respiratory Medicine Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial - The Lancet Respiratory Medicine](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/965c25ef-f1a8-470d-9a67-7a6c66c86e2a/gr1.gif)
Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial - The Lancet Respiratory Medicine
![Statistical controversies in clinical research: limitations of open-label studies assessing antiangiogenic therapies with regard to evaluation of vascular adverse drug events—a meta-analysis - Annals of Oncology Statistical controversies in clinical research: limitations of open-label studies assessing antiangiogenic therapies with regard to evaluation of vascular adverse drug events—a meta-analysis - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/4ba8a139-a98a-4306-9ae7-443a9ad74d47/gr1_lrg.jpg)
Statistical controversies in clinical research: limitations of open-label studies assessing antiangiogenic therapies with regard to evaluation of vascular adverse drug events—a meta-analysis - Annals of Oncology
![Expired Breath Carbon Monoxide Levels in a 14Week Open-Label Trial of... | Download Scientific Diagram Expired Breath Carbon Monoxide Levels in a 14Week Open-Label Trial of... | Download Scientific Diagram](https://www.researchgate.net/profile/James-Gold-2/publication/12050357/figure/fig1/AS:601716932231173@1520471904467/Expired-Breath-Carbon-Monoxide-Levels-in-a-14Week-Open-Label-Trial-of-Supportive-Group.png)
Expired Breath Carbon Monoxide Levels in a 14Week Open-Label Trial of... | Download Scientific Diagram
![Effects of open-label placebos on test performance and psychological well-being in healthy medical students: a randomized controlled trial | Scientific Reports Effects of open-label placebos on test performance and psychological well-being in healthy medical students: a randomized controlled trial | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-021-81502-2/MediaObjects/41598_2021_81502_Fig1_HTML.png)
Effects of open-label placebos on test performance and psychological well-being in healthy medical students: a randomized controlled trial | Scientific Reports
![A 2 × 2 factorial, randomised, open-label trial to determine the clinical and cost-effectiveness of hypertonic saline (HTS 6%) and carbocisteine for airway clearance versus usual care over 52 weeks in adults A 2 × 2 factorial, randomised, open-label trial to determine the clinical and cost-effectiveness of hypertonic saline (HTS 6%) and carbocisteine for airway clearance versus usual care over 52 weeks in adults](https://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs13063-019-3766-9/MediaObjects/13063_2019_3766_Fig1_HTML.png)
A 2 × 2 factorial, randomised, open-label trial to determine the clinical and cost-effectiveness of hypertonic saline (HTS 6%) and carbocisteine for airway clearance versus usual care over 52 weeks in adults
![Aspiration thrombectomy versus stent retriever thrombectomy as first-line approach for large vessel occlusion (COMPASS): a multicentre, randomised, open label, blinded outcome, non-inferiority trial - The Lancet Aspiration thrombectomy versus stent retriever thrombectomy as first-line approach for large vessel occlusion (COMPASS): a multicentre, randomised, open label, blinded outcome, non-inferiority trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/f21db88d-be5a-4c5c-8750-1a2940593250/gr1.gif)
Aspiration thrombectomy versus stent retriever thrombectomy as first-line approach for large vessel occlusion (COMPASS): a multicentre, randomised, open label, blinded outcome, non-inferiority trial - The Lancet
![Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial - The Lancet Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/f088fbaa-3134-4ce6-8294-01c8c23f249b/gr1.gif)
Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial - The Lancet
![Adaptive designs in clinical trials: why use them, and how to run and report them | BMC Medicine | Full Text Adaptive designs in clinical trials: why use them, and how to run and report them | BMC Medicine | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12916-018-1017-7/MediaObjects/12916_2018_1017_Fig1_HTML.gif)
Adaptive designs in clinical trials: why use them, and how to run and report them | BMC Medicine | Full Text
![Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study) - eClinicalMedicine Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study) - eClinicalMedicine](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/40b78dea-a1a9-4213-bee3-dc5db782df62/gr1.jpg)
Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study) - eClinicalMedicine
![An open-label, randomized trial of the combination of IFN-κ plus TFF2 with standard care in the treatment of patients with moderate COVID-19 - eClinicalMedicine An open-label, randomized trial of the combination of IFN-κ plus TFF2 with standard care in the treatment of patients with moderate COVID-19 - eClinicalMedicine](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2f77f968-1e6c-49f4-9f56-a42b48f4fb05/gr1.jpg)
An open-label, randomized trial of the combination of IFN-κ plus TFF2 with standard care in the treatment of patients with moderate COVID-19 - eClinicalMedicine
![Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial - The Lancet Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2b0c5fe8-d7eb-4483-b185-176f340ad2b7/gr1.gif)
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial - The Lancet
![Understanding Clinical Trial Terminology: What is an Open Label Clinical Trial? - Concert Pharmaceuticals Understanding Clinical Trial Terminology: What is an Open Label Clinical Trial? - Concert Pharmaceuticals](https://www.concertpharma.com/wp-content/uploads/2019/06/clinicaltrials-2-e1566478031946.jpg)
Understanding Clinical Trial Terminology: What is an Open Label Clinical Trial? - Concert Pharmaceuticals
PLOS ONE: Why do open-label placebos work? A randomized controlled trial of an open-label placebo induction with and without extended information about the placebo effect in allergic rhinitis
PLOS ONE: Adjunctive Aripiprazole Treatment for Risperidone-Induced Hyperprolactinemia: An 8-Week Randomized, Open-Label, Comparative Clinical Trial
![Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial) Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial)](https://bmjopen.bmj.com/content/bmjopen/5/12/e009562/F1.large.jpg)
Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial)
![Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open- label extension of the randomised, placebo-controlled, phase 3 trial - The Lancet Neurology Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open- label extension of the randomised, placebo-controlled, phase 3 trial - The Lancet Neurology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2883e24f-ded5-4447-96b4-db02193741ca/gr1.gif)
Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open- label extension of the randomised, placebo-controlled, phase 3 trial - The Lancet Neurology
![Open-label versus double-blind placebo treatment in irritable bowel syndrome: study protocol for a randomized controlled trial | Trials | Full Text Open-label versus double-blind placebo treatment in irritable bowel syndrome: study protocol for a randomized controlled trial | Trials | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13063-017-1964-x/MediaObjects/13063_2017_1964_Fig1_HTML.gif)